乳腺放疗技术对第二肺癌风险建模的影响:基于现代放疗技术临床肺部剂量的分析
该研究基于1690例韩国早期乳腺癌患者临床实际肺部剂量,采用RadRAT模型估算第二肺癌的超额终身风险(ELR)和相对风险(RR)。立体定向部分乳腺照射(PBI)和三维适形PBI的ELR中位数分别为2003和1931例/10万患者,容积旋转调强全乳照射(WBI)和三维适形WBI分别为2843和3738例/10万患者;两种PBI组ELR和RR均显著低于两种WBI组(Bonferroni校正P<.05)。
要点
- 基于临床肺部剂量的模型预测显示,早期乳腺癌放疗后第二肺癌风险随剂量增加而升高。
- 立体定向PBI和三维适形PBI的第二肺癌ELR显著低于容积旋转调强WBI和三维适形WBI。
- 两种PBI之间ELR无显著差异,该结果在按治疗分析中保持一致。
核心结论
- 模型预测提示韩国早期乳腺癌患者辅助放疗与剩余 lifetime 内肺癌风险剂量依赖性增加相关。
- 在低危乳腺癌选择PBI或WBI时,第二肺癌风险较低是众多考虑因素之一。
研究设计与样本
- 分析四个韩国早期乳腺癌患者队列,分别接受立体定向PBI、三维适形PBI、容积旋转调强WBI或三维适形WBI。
- 基于CT计划临床实际平均肺部剂量,转换为生物有效剂量(EQD2,α/β=3 Gy),用RadRAT在线计算器建模ELR和RR。
- 个体水平模型不确定性通过bootstrap重采样传播;主要分析固定暴露年龄50岁和治疗年份2026年,按治疗分析作为次要分析。
主要发现
- 共纳入1690例患者,其中3.8%(n=64)为当前或既往吸烟者。
- bootstrap中位ELR(例/10万患者):立体定向PBI 2003、三维适形PBI 1931、容积旋转调强WBI 2843、三维适形WBI 3738。
- 两种PBI组ELR和RR均显著低于两种WBI组(Bonferroni校正P<.05),两种PBI组间无显著差异,次要按治疗分析结果一致。
- RR范围为1.54至2.05,总终身风险从基线3.6%升至PBI组5.5-5.6%、WBI组6.4-7.3%。
关键数值与推荐
- 中位ELR:立体定向PBI 2003例/10万患者;三维适形PBI 1931例/10万患者;容积旋转调强WBI 2843例/10万患者;三维适形WBI 3738例/10万患者。
- RR范围1.54-2.05;总终身风险基线3.6%,PBI组5.5-5.6%,WBI组6.4-7.3%。
- PBI组与WBI组ELR和RR差异Bonferroni校正P<.05。
临床怎么用
- 对于低危早期乳腺癌,选择PBI而非WBI可降低模型预测的第二肺癌终身风险。
- 第二肺癌风险应作为PBI与WBI决策中的众多考量因素之一。
局限性
- 结论基于模型预测而非实际观察到的第二肺癌发生率。
- 研究对象为韩国患者,吸烟者比例较低(3.8%),外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this paper is to estimate the projected lifetime risk of secondary lung cancer associated with breast radiation therapy-based on actual clinically delivered lung doses for various modern radiation techniques and target volumes. METHODS AND MATERIALS: Four cohorts consisting of Korean patients with early-stage breast cancer were analyzed, treated with either stereotactic partial breast irradiation (PBI), 3-dimensional-conformal PBI, volumetric modulated arc therapy whole breast irradiation (WBI), or 3-dimensional-conformal WBI. Using the clinically delivered mean lung dose from computed tomography-based dose planning, converted to biologically effective dose (EQD2, α/β = 3 Gy), we modeled the excess lifetime risk (ELR) and relative risk (RR) of secondary lung cancer using the RadRAT online calculator. Individual-level model uncertainty was propagated via bootstrap resampling. Age at exposure and treatment year were fixed at 50 years and 2026 (primary analysis); an as-treated analysis served as secondary. RESULTS: A total of 1690 patients were included, among whom 3.8% (n = 64) were current or former smokers. The bootstrap-based median ELR of secondary lung cancer was 2003, 1931, 2843, and 3738 cases per 100,000 patients in the stereotactic PBI, 3D-conformal PBI, volumetric modulated arc therapy WBI, and 3D-conformal WBI cohorts, respectively. Both PBI groups had significantly lower ELR and RR than the 2 WBI groups (Bonferroni-corrected P < .05), whereas the 2 PBI groups did not differ significantly from each other; these findings remained consistent in the secondary as-treated analysis. The RR ranged from 1.54 to 2.05, increasing the total lifetime risk from a baseline of 3.6% to 5.5-5.6% in the PBI groups and 6.4-7.3% in the WBI groups. CONCLUSIONS: Model-based projections suggest that adjuvant radiation therapy in patients with early-stage breast cancer is associated with a dose-dependent increase in the risk of developing lung cancer during the remaining lifetime in Korean patients. A lower risk for secondary lung cancer is one of many factors to consider when deciding between PBI and WBI in low-risk breast cancer.
引用
- Hoekstra N, Kim DH, Vicini FA, et al. The Impact of Breast Radiation Technique on Secondary Lung Cancer Risk Modeling: An Analysis based on Clinically Delivered Lung Doses of Various Modern Radiation Techniques and Target Volumes. Int J Radiat Oncol Biol Phys. 2026. PMID: 42419586. doi:10.1016/j.ijrobp.2026.06.3082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。